Class of 2012: Peter Marszal

Peter MarszalMBiotech Class of 2012: Peter Marszal
Surgical Representative, Zimmer ONE

Peter Marszal is currently a Surgical Representative at Zimmer ONE, a distributorship specializing in orthopaedic implants as well as other products related to the orthopaedic industry. Hired while still undertaking his graduate studies at the University of Toronto, Peter now works as part of a small team supplying the Greater Toronto Area. His individual territory primarily consists of two of the largest orthopaedic accounts in Canada - Sunnybrook Health Sciences Centre and The Holland Musculoskeletal Centre. His specializations include the primary knee, primary hip, and revision knee portfolios. He is also a part of the ZONE (Zimmer ONE) Trauma On-call Team responsible for servicing Trauma accounts, including level I trauma centres across the GTA.

Prior to his switch to Zimmer ONE, Peter was a Forecasting Associate at AstraZeneca Pharmaceuticals. This role primarily consisted of gathering data necessary to building forecasting models with a focus on the Oncology portfolio.

Throughout his two years in the MBiotech program, Peter, as part of Team IQ, repeatedly performed in the top tier of their class. In BTC1800H - Biotech in Medicine, the team developed a novel approach to collecting health outcome data on drug use in hospitals, and examined the potential for supplying the data to industry and government. This resulted in a presentation to the Ministry of Health in 2011 for funding, as well as a Provincial wide clinical study funding submission to CIHR involving 10 teaching hospitals, based entirely upon the student work performed for their project in Biotech in Medicine. It was for this project that the team received the prestigious MBiotech Innovator award, an award given once a year to the team who has presented the most innovative project in Biotech in Medicine, as part of a supervised study, or during the AstraZeneca Seminar Series.

As Part of a separate elective project, Peter worked as part of another team providing reimbursement consulting support to, and
working very closely with, Dublin based Biotech startup Crescent Diagnostics Inc. The purpose of the project was to determine how a new
technology for bone density scanning could potentially facilitate off label treatment decisions, and ultimately create a novel revenue
stream. The solution was presented to the MBiotech class, faculty, and the company's directors during an AstraZeneca seminar.

For Peter, the value gained from a MBiotech education has been diverse and applicable. The intimate understanding of the Biotechnology arena from both an academic and industry perspective has been an invaluable asset while working as a representative from the private sector in academic institutions. The experience gained from numerous projects and presentations has accelerated a maturation in professionalism and enhanced his ability to work efficiently as part of a team. It is the reasons listed, along with extensive industry network opportunities
provided by the program, that make the MBiotech Masters second to none.